Evaluation of oral anticoagulation therapy: Rationale and design of the thrombEVAL study programme

European Journal of Preventive Cardiology

Volumn 22, Issue 5, 2015, Pages 622-628

  Prochaska, Jürgen H ^a   Coldewey, Meike ^a   Göbel, Sebastian ^a   Keller, Karsten ^a   Hendelmeier, Martin ^a   Konstantinides, Stavros ^a   Münzel, Thomas ^a   Wild, Philipp S ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Anticoagulants; coagulation service; phenprocoumon; quality of care; regular medical care; study design; vitamin K antagonist

Indexed keywords

ANTIVITAMIN K; ANTICOAGULANT AGENT; PHENPROCOUMON; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; COHORT ANALYSIS; EMBOLISM; FOLLOW UP; HEALTH CARE; HEART INFARCTION; HUMAN; LONG TERM CARE; MEDICAL CARE; MORTALITY; PRIORITY JOURNAL; QUALITY CONTROL; TELEMEDICINE; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; HEALTH CARE QUALITY; METHODOLOGY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PROCEDURES; PROSPECTIVE STUDY; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; HUMANS; PHENPROCOUMON; PROSPECTIVE STUDIES; QUALITY OF HEALTH CARE; RESEARCH DESIGN; TELEMEDICINE; THROMBOEMBOLISM; VITAMIN K;

EID: 84927627329     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487314527852     Document Type: Article

References (32)

1. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999 ; 131: 492-501
2. Hirsh J, Fuster V, Ansell J, et al. American Heart Association and American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003 ; 107: 1692-1711
3. Kretschmer GG, Herbst FF, Prager MM, et al. A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. Arch Surg. 1992 ; 127: 1112-1115
4. Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 ; 141: e576S-e600S
5. Wilke T, Groth A, Mueller S, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace. 2013 ; 15: 486-493
6. Herwaarden MF, Roukens M, Pop GA, et al. Adherence to guidelines for the prescribing of double and triple combinations of antithrombotic agents. Eur J Prev Cardiol. 2014 ; 21: 231-243
7. Ademi Z, Pasupathi K, Liew D. Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia. Eur J Prev Cardiol. 2013 ;:
8. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 ; 141: e152S-e84S
9. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007 ; 167: 239-245
10. Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest. 2004 ; 126: 1938-1945
11. Witt DM, Delate T, Clark NP, et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood. 2009 ; 114: 952-956
12. Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993 ; 69: 236-239
13. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008 ; 118: 2029-2037
14. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 ; 361: 1139-1151
15. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 ; 365: 883-891
16. Baker WL, Cios DA, Sander SD, et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009 ; 15: 244-252
17. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999 ; 131: 927-934
18. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998 ; 158: 1641-1647
19. Nichol MB, Knight TK, Dow T, et al. Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care. Ann Pharmacother. 2008 ; 42: 62-70
20. Errichetti AM, Holden A, Ansell J. Management of oral anticoagulant therapy. Experience with an anticoagulation clinic. Arch Intern Med. 1984 ; 144: 1966-1968
21. van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006 ; 129: 1155-1166
22. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005 ; 26: 2422-2434
23. Kelly JG, O'Malley K. Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacokinet. 1979 ; 4: 1-15
24. Gadisseur APA, Breukink-Engbers WGM, van der Meer FJM, et al. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial. Arch Intern Med. 2003 ; 163: 2639-2646
25. Fihn SD, Gadisseur AAP, Pasterkamp E, et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost. 2003 ; 90: 260-266
26. Eikelboom JW, Weitz JI. New anticoagulants. Circulation. 2010 ; 121: 1523-1532
27. Statistisches Bundesamt. Statistisches jahrbuch 2012-Deutschland und Internationales, Hagenkort-Rieger S (ed). Statistisches Bundesamt, 2012.
28. Kroenke K, Spitzer RL, Williams JBW. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003 ; 41: 1284-1292
29. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction. 1993 ; 88: 791-804
30. Samsa G, Matchar DB, Dolor RJ, et al. A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation. Health Qual Life Outcomes. 2004 ; 2: 22-22
31. Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis. 2003 ; 15: 213-216
32. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008 ; 1: 84-91